Literature DB >> 6792848

Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture.

S Jozan, B Kreitmann, F Bayard.   

Abstract

The effects of oestradiol (Oe2), oestrone (Oe1), oestriol (Oe3), oestetrol (Oe4) on the induction of the progesterone receptor (PgR) and growth of MCF-7 cells are compared. All the four oestrogens increased cell PgR concentration. Analysis of the dose-response curves shows induction by Oe2 to be 10 times and 50 times greater than Oe3 and Oe4, respectively. Oe1 and Oe2 are equally effective, even with consideration of metabolic conversion of O31 into Oe2. When compared with untreated cells, Oe2, Oe3, and Oe4 do not influence significantly the plating efficiency but all 3 hormones increase thymidine incorporation of the cells in log phase growth. Oe2, Oe3 and Oe4 are able to rescue the growth inhibition induced by antioestrogens. The respective potency compared to Oe2 is again in the range of 10 and 50 times lower for Oe3 and Oe4, respectively. On the other hand Oe1 decreases plating efficiency, thymidine incorporation and does not rescue the growth inhibition induced by antioestrogens when the metabolic conversion of Oe1 into Oe2 is prevented. Thus, Oe3 and Oe4 behave like complete Oe2 agonists whereas Oe1 has dissociated effects, agonist on PgR induction and antagonist on cell growth.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6792848     DOI: 10.1530/acta.0.0980073

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  7 in total

Review 1.  Enzymatic regulation of estradiol-17 beta concentrations in human breast cancer cells.

Authors:  J B Adams
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

2.  Physicochemical and genetic evidence for specific antiestrogen binding sites.

Authors:  J C Faye; S Jozan; G Redeuilh; E E Baulieu; F Bayard
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

3.  Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells.

Authors:  A Valentin-Opran; G Eilon; S Saez; G R Mundy
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

Review 4.  Estetrol and Mammary Gland: Friends or Foes?

Authors:  Anne Gallez; Isabelle Dias Da Silva; Vincent Wuidar; Jean-Michel Foidart; Christel Péqueux
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-08-31       Impact factor: 2.673

Review 5.  Estetrol: A New Choice for Contraception.

Authors:  Franca Fruzzetti; Tiziana Fidecicchi; Maria Magdalena Montt Guevara; Tommaso Simoncini
Journal:  J Clin Med       Date:  2021-11-29       Impact factor: 4.241

6.  Estetrol Combined to Progestogen for Menopause or Contraception Indication Is Neutral on Breast Cancer.

Authors:  Anne Gallez; Silvia Blacher; Erik Maquoi; Erika Konradowski; Marc Joiret; Irina Primac; Céline Gérard; Mélanie Taziaux; René Houtman; Liesbet Geris; Françoise Lenfant; Elisabetta Marangoni; Nor Eddine Sounni; Jean-Michel Foidart; Agnès Noël; Christel Péqueux
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

7.  Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms.

Authors:  Céline Gérard; Mélanie Mestdagt; Ekaterine Tskitishvili; Laudine Communal; Anne Gompel; Elisabete Silva; Jean-François Arnal; Françoise Lenfant; Agnès Noel; Jean-Michel Foidart; Christel Péqueux
Journal:  Oncotarget       Date:  2015-07-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.